| Literature DB >> 23786263 |
Naama E Toledano Furman1, Yael Lupu-Haber, Tomer Bronshtein, Limor Kaneti, Nitzan Letko, Eyal Weinstein, Limor Baruch, Marcelle Machluf.
Abstract
The ultimate goal in cancer therapy is achieving selective targeting of cancer cells. We report a novel delivery platform, based on nanoghosts (NGs) produced from the membranes of mesenchymal stem cells (MSCs). Encompassing MSC surface molecules, the MSC-NGs retained MSC-specific in vitro and in vivo tumor targeting capabilities and were cleared from blood-filtering organs. MSC-NGs were found to be biocompatible. Systemic administration of drug loaded MSC-NGs demonstrated 80% inhibition of human prostate cancer.Entities:
Mesh：
Substances：
Year: 2013 PMID： 23786263 DOI： 10.1021/nl401376w
Source DB: PubMed Journal: Nano Lett ISSN： 1530-6984 Impact factor: 11.189